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Abstract
Background: Carbapenem antibiotics are considered the treatment of choice for serious extended-spectrum beta-
lactamase (ESBL)-producing Gram-negative bacteria (GNB) infections. The study objectives were to evaluate efficacy
and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-
lactamase-producing Enterobacteriaceae.
Methods: We conducted a randomized controlled trial of adult patients with documented ESBL-producing
Enterobacteriaceae infections who had received any group 2 carbapenem for less than 96 h. In the intervention
group, the previously-prescribed group 2 carbapenem was de-escalated to ertapenem. In the control group, the
group 2 carbapenem was continued.
Results: During June 2011–December 2014, 32 patients were randomized to the de-escalation group and 34 to the
control group. Most common sites of infection were urinary tract infection (42%). Characteristics of both groups
were comparable. By using a 15% predefined margin, ertapenem was non-inferior to control group regarding the
clinical cure rate (%Δ = 14.0 [95% confidence interval: −2.4 to 31.1]), the microbiological eradication rate (%Δ = 4.1
[−5.0 to 13.4]), and the superimposed infection rate (%Δ = −16.5 [−38.4 to 5.3]). Patients in the de-escalation group
had a significantly lower 28-day mortality rate (9.4% vs. 29.4%; P = .05), a significantly shorter median length of stay
(16.5 days [4.0–73.25] vs. 20.0 days [1.0–112.25]; P = .04), and a significantly lower defined daily dose of carbapenem
use (12.9 ± 8.9 vs. 18.4 ± 12.6; P = .05).
Conclusions: Ertapenem could be safely used as de-escalation therapy for ESBL-producing Enterobacteriaceae
infections, once the susceptibility profiles are known. Future studies are needed to investigate ertapenem efficacy
against ESBL-producing Enterobacteriaceae pneumonia to determine its applicability in life-threatening conditions.
Trial registration: ClinicalTrials.gov identifier: NCT01297842. Registered on 14 February 2011. First patient enrolled
on 27 June 2011.
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Background
Empirical broad-spectrum antimicrobial therapy is
highly recommended in patients with serious infections
in aiming to improve patient’s outcomes [1]. However,
overuse of broad spectrum antimicrobial therapy is an
important risk factor for the emergence of bacterial re-
sistance [2]. De-escalation therapy has been proposed as
a strategy for balancing the advantages of adequate em-
pirical therapy with the risk of emergence of bacteria re-
sistance [3]. De-escalation therapy involves the initial
use of empirical broad-spectrum antimicrobial therapy,
which is then streamlined to more narrow-spectrum or
targeted agents once culture and susceptibilities are
available [4]. Efficacy of de-escalation therapy in patients
with severe infections has been confirmed in many pre-
vious studies [5–7].
There are two carbapenem groups currently available
worldwide: group 1 carbapenem (i.e.,ertapenem) and
group 2 carbapenems (i.e., imipenem, meropenem, dori-
penem, and biapenem). Group 2 carbapenems are potent
antibiotics that act against Gram-positive bacteria and
Gram-negative bacteria, including extended-spectrum
beta-lactamase-producing Enterobacteriaceae, Pseudo-
monas aeruginosa, and Acinetobacter spp. As compared
to group 2 carbapenems, ertapenem is not active against
P. aeruginosa and Acinetobacter spp. [8]. Nevertheless, a
recent systematic review did not find a significant differ-
ence in resistant Enterobacteriaceae colonization be-
tween patients who received ertapenem and patients
who received group 2 carbapenems [9].
Carbapenem antibiotics are considered the treatment of
choice for serious infections caused by ESBL-producing
Enterobacteriaceae [10]. Many studies have reported that
ertapenem has promising efficacy as definitive therapy for
these serious infections, but the majority of these studies
were observational studies [11–13]. Based on results from
a recent propensity score-matching cohort study, ertape-
nem appears as effective as group 2 carbapenems for em-
pirical and definitive therapy of bloodstream infections
caused by ESBL-producing Enterobacteriaceae [14].
Group 2 carbapenems have to be administered paren-
terally at least twice a day, while ertapenem is generally
administered once daily and can be given by intramuscu-
lar injection [8]. However, the maximum serum concen-
tration of ertapenem is slightly lower after intramuscular
administration compared with intravenous administra-
tion [15].
Therefore, some clinically stable patients could receive
ertapenem as outpatient parenteral antibiotic therapy,
which would have the effect of reducing both length of
stay and hospital expenditure.
Given these considerations, an open-label randomized
controlled trial was conducted in patients with docu-
mented ESBL-producing Enterobacteriaceae infections
who had received group 2 carbapenems as empirical
therapy. The aim was to compare the efficacy and safety
of de-escalation therapy to ertapenem versus continu-
ation of group 2 carbapenem antibiotics. Efficacy, re-
source use, and impact on emergence of bacterial
resistance were investigated and determined.
Methods
Setting and study design
A single-center, open-label, randomized equivalence
trial was conducted from June 2011 to December 2014
at Siriraj Hospital, a 2200-bed tertiary care university
hospital in Bangkok, Thailand.
Study subjects
Eligible subjects were hospitalized patients aged 18 years
or older who had documented ESBL-producing Entero-
bacteriaceae infections and who received group 2 carba-
penems as empirical therapy. Exclusion criteria were, as
follows: treatment with a group 2 carbapenem for longer
than 96 h; having active P. aeruginosa co-infection;
pregnancy; breast-feeding; having a history of carba-
penem hypersensitivity; and having infection caused by
carbapenem-resistant Enterobacteriaceae strain.
Randomization and treatment
Eligible subjects were 1:1 allocated to the intervention
group or the control group by stratified randomization
according to the site of infection (lower respiratory tract
infection, urinary tract infection (UTI), and bacteremia).
Centers for Disease Control and Prevention/National
Healthcare Safety Network (CDC/NHSN) surveillance
definitions for specific types of healthcare-associated in-
fections (HAIs) were used for diagnosis of each type of
infection [16]. Randomization numbers were computer-
generated with permuted blocks (block size of four).
For patients in the intervention group (de-escalation
group), the previously prescribed group 2 carbapenem
was de-escalated to ertapenem. For patients in the con-
trol group, the group 2 carbapenem was continued for
the entire course of therapy. Carbapenem dosage was
adjusted according to patient renal function, as shown in
the products’ package insert. Renal function was calcu-
lated using Cockcroft-Gault formula. Each dose of either
gr.1 or gr.2 carbapenem was given by infusion for 1 h.
Extended infusion or continuous infusion of carbapenem
was not allowed in this study. Duration of systemic anti-
biotic therapy was determined by each patient’s attend-
ing physicians. All other non-carbapenem antibiotics
were given as needed.
Microbiological testing
Microbiological tests were routinely processed at our hos-
pital’s microbiology laboratory. All tests were processed by
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a Vitek® 2 automated ID/AST instrument (bioMerieux SA,
Marcy-l'Étoile, France). ESBL production was confirmed
by double-disk method, according to the performance
standards for antimicrobial susceptibility testing estab-
lished by the Clinical and Laboratory Standards Institute
(CLSI) [17].
Clinical specimens from the documented site of infec-
tion were obtained on day 3, day 7, day 14, and then at
least once a week thereafter for microbiological culture.
Specimen collection was discontinued if the culture re-
sult was negative or the course of antibiotic treatment
was completed. To determine colonization by resistant
Gram-negative pathogens, a stool culture or a rectal
swab culture was obtained on day 0, at the end of ther-
apy, and on day 28 of therapy if there were no contrain-
dications. The target resistant Gram-negative pathogens
were ESBL-producing Enterobacteriaceae, multidrug-
resistant (MDR) P. aeruginosa, and MDR A. baumannii.
Data collection and outcome assessment
Baseline data, including demographic characteristics,
underlying diseases, Acute Physiology and Chronic
Health Evaluation II (APACHE II) score, intensive care
unit (ICU) admission, and previous antibiotic therapy
were collected. Clinical outcomes were evaluated on a
daily basis. Cost-related data, including length of stay
(LOS) and amount of drug therapy for ESBL-producing
Enterobacteriaceae were also collected. All adverse
events were recorded for 28 days from the date of
enrollment.
The primary outcome was clinical cure rate at the end
of therapy. Secondary outcomes included microbio-
logical eradication rate, superimposed infection rate dur-
ing study treatment, 28-day mortality rate, and adverse
drug reactions (ADRs). Prevalence of colonization with
resistant pathogens and economic outcomes (LOS, anti-
biotic consumption, and hospital expenditure) were also
evaluated. Study definitions are shown in Table 1.
Statistical analysis
Based on data obtained from our pilot study [unpub-
lished data], the estimated clinical cure rate of group 2
carbapenems in the treatment of ESBL-producing En-
terobacteriaceae infection is approximately 90%. To test
the equivalency hypothesis with a predefined margin of
±15% using a 2-sided confidence interval (CI) approach,
the required sample size was calculated to be 100 pa-
tients or 50 patients for each of two groups. However,
the study was terminated early due to slow recruitment
of eligible subjects. As such, this study describes an in-
terim analysis of 66 enrolled patients. Data are presented
as n (%), mean ± standard deviation (SD), or median
[range]. Treatment outcomes are reported as % differ-
ence (%Δ, % of the de-escalation group - % of the con-
trol group) and 95% CI. Intention to treat analysis was
used for all analyses. All statistical calculations were per-
formed using STATA version 14.0/IC (StataCorp LP,
College Station, TX, USA).
Results
From June 2011 to December 2014, 484 patients with
documented ESBL-producing Enterobacteriaceae infec-
tion were empirically treated with group 2 carbapenems
at our medical center. Sixty-six of those patients satisfied
the inclusion criteria and were enrolled in this study
(Fig. 1). Thirty-two patients were randomized into the
de-escalation group (intervention group) and 34 into the
non-de-escalation group (control group). De-escalation
group patients were de-escalated to ertapenem and non-
de-escalation group patients were continued with their
previously prescribed group 2 carbapenem. Demo-
graphic and clinical characteristics between groups were
comparable (Table 2). Nearly 60% of patients were
female, with a mean age of 64.8 years (67.5 ± 17.2 years
in the de-escalation group and 62.2 ± 21.6 years in the
non-de-escalation group).
Twelve patients (37.5%) in the de-escalation group and
20 patients (58.8%) in the non-de-escalation group had a
healthcare-associated infection (P = .08). Approximately
40% of patients in both groups had urinary tract as the
site of ESBL-producing Enterobacteriaceae infection.
Fourteen patients in the de-escalation group (43.8%) and
12 patients in the non-de-escalation group (35.3%) had
primary bacteremia. The mean APACHE II score and
mean modified APACHE II score were comparable be-
tween groups. Mean time from onset of infection to
enrollment was 4.2 ± 1.6 days in the de-escalation
group and 4.5 ± 1.2 days in the non-de-escalation
group (P = .47). There was no significant difference in
duration of pre-enrollment use of group 2 carbapenems
(3.1 ± 1.5 days vs. 2.6 ± 1.7 days; P = .29) or duration of
pre-enrollment use of any other antibiotic (3.3 ± 5.4 days
Table 1 Study definitions
Terms Definitions
Clinical cure Resolution of or improvement in the index




At least one negative culture of an index
pathogen from a clinical specimen that was
obtained during or after the course of
antibiotic therapy
Superimposed infection New onset of infection caused by any
pathogens other than ESBL-producing
Enterobacteriaceae during the course
of antibiotic therapy
28-day mortality Death from any cause within 28 days
after enrollment
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vs. 3.0 ± 6.3; P = .82) between the de-escalation and non-
de-escalation groups, respectively.
Clinical, microbiological and cost-related outcomes of
patients in the de-escalation group (intervention) and in
the non-de-escalation group (control) are shown in
Table 3. This study failed to prove equivalency in all
clinical outcomes, including clinical cure rate (%Δ = 14.0
[95% CI: -2.4 to 31.1]), microbiological eradication rate
(%Δ = 4.1 [-5.0 to 13.4]), superimposed infection (%Δ
= -16.5 [-38.4 to 5.3]), and 28-day mortality (%Δ = -20.0
[-39.3 to -0.8]). Although the equivalency hypothesis was
not proven, the lower bounds of the CIs for difference in
clinical cure and microbiological eradication rate were
within the -15% margin. The upper bounds of the CIs
for difference in 28-day mortality and superimposed
infection were within the +15% margin. Therefore,
non-inferiority of de-escalation was established for all
primary and secondary outcomes. Additionally, the
upper bound of the CI for difference in 28-day mortal-
ity was below zero, probably suggesting the superiority
of de-escalation for 28-day mortality.
Superimposed infection rate was slightly lower
among patients in the de-escalation group (18.8% vs.
35.3%; p = 0.13). The three leading causative pathogens
of superimposed infection were MDR A. baumannii,
methicillin-resistant Staphylococcus aureus, and Can-
dida spp. There was no significant difference in the
distribution of causative pathogens between groups.
Patients in the de-escalation group had a significantly
shorter median length of hospital stay (16.5 days [4.0-
73.0] vs. 20.0 days [1.0-112.0]; p = .04) and a significantly
lower defined daily dose (DDD) of carbapenem antibiotic
use (12.9 ± 8.9 vs. 18.4 ± 12.6; p = .05). There were no sig-
nificant differences in stool colonization by MDR patho-
gens at enrollment or at the end of therapy.
Ertapenem was discontinued early in one patient due
to the development of neurological side effects, includ-
ing dizziness and headache. All neurological symptoms
subsided after ertapenem was switched to meropenem.
There was no early discontinuation in the non-de-
escalation group that related to adverse drug reaction
(ADRs). There was no statistical difference in ADRs be-
tween groups.
Discussion
The findings of this study indicate that de-escalation
therapy to ertapenem is non-inferior to continuation of
group 2 carbapenems for clinical cure rate, microbio-
logical eradication rate, and superimposed infection rate.
These findings confirm the efficacy of ertapenem and
are consistent with the findings of previously docu-
mented in many observational cohort studies [11–14].
The slightly lower rate of superimposed infections
among patients in the de-escalation group also sup-
ported the findings of previous studies that ertapenem
has lower collateral impact. Further, the lower rate of
superimposed infections may be a contributing factor to
the significantly lower 28-day mortality rate among
Fig. 1 Study flow chart
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Table 2 Characteristics of patients in the de-escalation group (intervention) and in the non-de-escalation group (control)
Variables All (n = 66) De-escalation (n = 32) Non-de-escalation (n = 34) P-value
Baseline characteristics
Mean age, years 64.8 ± 19.6 67.5 ± 17.2 62.2 ± 21.6 0.28
Female 38 (57.6%) 19 (59.4%) 19 (55.9%) 0.81
Medicine ward 58 (87.9%) 26 (81.3%) 32 (94.1%) 0.11
Underlying disease
● Hypertension 37 (56.1%) 19 (59.4%) 18 (52.9%) 0.60
● Cerebrovascular disease 15 (22.7%) 9 (28.1%) 6 (17.7%) 0.31
● Chronic lung disease 10 (15.2%) 2 (6.3%) 8 (23.5%) 0.08
● Cardiovascular disease 22 (33.3%) 11 (34.4%) 11 (32.4%) 0.86
● Diabetes mellitus 25 (37.9%) 11 (34.4%) 14 (41.2%) 0.57
● Chronic kidney disease 23 (34.9%) 12 (37.5%) 11 (32.4%) 0.66
● Chronic liver disease 7 (10.6%) 3 (9.4%) 4 (11.8%) 1.00
● Malignancy 17 (26.6%) 9 (28.1%) 8 (23.5%) 0.67
● Any immunocompromised conditiona 16 (24.2%) 7 (21.9%) 9 (36.5%) 0.66







Modified APACHE II score at enrollmentc 8.9 ± 4.9 8.9 ± 5.1 8.9 ± 4.9 0.94
● History of organ insufficiency 35 (53.9%) 20 (62.5%) 15 (45.5%) 0.17
● Emergency surgery 8 (12.1%) 5 (15.6%) 3 (8.8%) 0.47
● Acute renal failure 8 (12.1%) 8 (25.0%) 0 (0.0%) 0.002
● ICU admission 3 (4.6%) 2 (6.3%) 1 (2.9%) 0.42
Characteristics of infections
Hospital-acquired infection 32 (48.5%) 12 (37.5%) 20 (58.8%) 0.08
Site of infection at enrollment 1.00
● Urinary tract infection 27 (40.9%) 13 (40.6%) 14 (41.2%)
● Pneumonia 11 (16.7%) 5 (15.6%) 6 (16.7%)
● Others 29 (43.9%) 14 (43.8%) 15 (44.1%)
● Primary bacteremia 26 (78.8%) 14 (82.4%) 12 (75.0%)
● Skin infection 1 (1.5%) 0 1 (2.9%)
● Reproductive tract infection 1 (1.5%) 0 1 (2.9%)
● Gastrointestinal tract infection 1 (1.5%) 0 1 (2.9%)
Having bacteremia 33 (50.0%) 17 (53.1%) 16 (47.1%) 0.62
Cause of bacteremiad (n = 17) (n = 16) 0.57
● Primary bacteremia 26 (78.8%) 14 (82.4%) 12 (75.0%)
● Urinary tract infection 5 (15.2%) 3 (17.6%) 2 (12.5%)
● Catheter-related infection 2 (6.0%) 0 2 (12.5%)
Causative pathogene
● Escherichia coli 46 (69.7%) 24 (75.0%) 22 (64.7%) 0.36
● Klebsiella spp. 21 (31.8%) 8 (25.0%) 13 (38.2%) 0.25
Mean time from onset of infection to enrollment, days 4.3 ± 1.4 4.2 ± 1.6 4.5 ± 1.2 0.47
Mean duration of pre-enrollment use of group 2 carbapenems, days 2.8 ± 1.6 3.1 ± 1.5 2.6 ± 1.7 0.29
Mean duration of pre-enrollment use of any antibiotics, days 3.1 ± 5.8 3.3 ± 5.4 3.0 ± 6.3 0.82
aAny immunocompromised condition (e.g., HIV infection, receipt of immunosuppressive agents (steroid, cytotoxic agents, and/or chemotherapy))
bAPACHE II score was calculated using data from 10 patients with available arterial blood gas results
cModified APACHE II score was calculated in all patients. For those who did not have arterial blood gas results, the arterial pH was substituted by the level of
serum bicarbonate
dAll patients with secondary bacteremia due to UTI (n = 5) were enrolled into the UTI stratum. Other cases of secondary bacteremia were due to cellulitis (n = 1)
and spontaneous bacterial peritonitis (n = 1)
eOne patient in the group 2 carbapenems group had bacteremia caused by both Escherichia coli and Klebsiella spp
Abbreviation: APACHE II Acute Physiology and Chronic Health Evaluation II
Data are presented as n (%), mean ± SD; P-value < 0.05 indicates statistical significance
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patients in the de-escalation group. Given that the patients
in the de-escalation group were slightly older and sicker
than those in the non-de-escalation group, the lower 28-
day mortality among the de-escalation group was unlikely
to be the results of unbalanced baseline characteristics.
Similar to results from a recent systematic review, our
study did not find any significant difference in stool
colonization by MDR pathogens. However, our baseline
rate of colonization with resistant GNB pathogen was
relatively high (>60%), compared with the studies in-
cluded in another systematic review [9].
Patients in the de-escalation group also had a signifi-
cantly shorter length of hospital stay, as well as a signifi-
cantly lower defined daily dose (DDD) of carbapenem use.
This can be simply explained by the practice of once-daily
dosing of ertapenem [8], whereby some clinically stable
patients could be discharged early and treated with paren-
teral antimicrobial therapy as outpatients.
This study has several inherent strengths. While most
previous studies were observational, this was a random-
ized controlled trial. Randomization ensured a balance
of measured and unmeasured confounders between the
intervention and control groups. In addition to the
evaluation of clinical outcomes, other important param-
eters, including stool colonization with resistant GNB
and cost-related outcomes were evaluated.
This study also has some mentionable limitations.
First, participation bias and observer bias may have
Table 3 Outcomes of patients in the de-escalation group (intervention) and in the non-de-escalation group (control)
Outcomes De-escalation (n = 32) Non-de-escalation (n = 34) P-value
Clinical outcomes
Clinical cure rate 30 (93.8%) 24 (79.4%) 0.09
Microbiological eradication ratea 20/20 (100.0%) 23/24 (95.8%) 0.36
28-day mortality rate 3 (9.4%) 10 (29.4%) 0.05b
• ID-related mortality 1 (3.1%) 9 (26.5%) 0.01b
• Non ID-related mortality 1 (3.1%) 1 (2.9%) 1.00b
Superimposed infection rate 6 (18.8%) 12 (35.3%) 0.13
• Acinetobacter baumannii 2 (6.3%) 6 (17.3%) 0.26b
• MRSA 2 (6.3%) 3 (8.8%) 1.00b
• Candida spp. 1 (3.1%) 4 (11.8%) 0.51b
• Pseudomonas aeruginosa 2 (6.3%) 2 (5.9%) 1.00b
• Enterococcus spp. 2 (6.3%) 0 0.23b
Cost-related outcomes
Median length of stay, days 16.5 (4.0–73.0) 20.0 (1.0–112.0) 0.04b
Median length of stay after enrollment, days 9.5 (0–37.0) 11.5 (1.0–102.0) 0.11b
Mean duration of carbapenem use, days 14.4 ± 6.0 16.5 ± 10.5 0.32
Mean DDD of carbapenem 12.9 ± 8.9 18.4 ± 12.6 0.05
Stool colonization N = 32 N = 32c
At baseline
• Any MDR bacteria 20 (62.5%) 21 (65.6%) 1.0
• Any ESBL-producing GNB 19 (59.4%) 20 (62.5%) 1.0
• MDR-Acinetobacter baumannii 4 (12.5%) 3 (9.4%) 1.0b
• MDR-Pseudomonas aeruginosa 0 1 (3.1%) 1.0b
At the end of therapy
• Any MDR bacteria 16 (50.0%) 11 (34.4%) 0.31
• Any ESBL-producing GNB 11 (34.4%) 8 (25.0%) 0.59
• MDR-Acinetobacter baumannii 6 (18.8%) 4 (12.5%) 0.73b
• MDR-Pseudomonas aeruginosa 1 (3.1%) 0 (0.0%) 1.0b
aMicrobiological eradication was calculated in patients who had a follow-up culture of the infection site
bNonparametric test
cTwo patients in the group 2 carbapenem group had a contraindication for rectal swab culture
Abbreviations: MRSA methicillin-resistant Staphylococcus aureus, DDD defined daily dose, MDR multi-drug resistant, ESBL extended-spectrum beta-lactamase
enzyme, GNB Gram-negative bacteria
Data are presented as n (%), mean ± SD or median (range); P-value < 0.05 indicates statistical significance
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occurred because the study design was open-label. How-
ever, the microbiological cure rate and 28-day mortality
rate are objective measures, so observer bias would have
been minimal. Second, the majority of patients in this
study had UTI or primary bacteremia, with only a small
proportion having pneumonia. Thus, we are not able to
conclude that de-escalation to ertapenem is effective
against ESBL-producing Enterobacteriaceae pneumonia.
Third, the study was early terminated before achieving
the target sample size, therefore all statistically signifi-
cant findings are less reliable. Lastly, the study was de-
signed to stratify only on the site of infection but did not
stratify on other clinically significant factors such as age
and APACHE score. Nevertheless, these two important
factors were comparable between two groups.
Conclusions
Based on the results of this study, ertapenem can be safely
used as de-escalation therapy for ESBL-producing Entero-
bacteriaceae infections, especially UTIs and primary
bacteremia. Future studies are needed to investigate
ertapenem efficacy against ESBL-producing Enterobac-
teriaceae pneumonia to determine its applicability in
life-threatening conditions. Additionally, a study in the
cost-effectiveness of de-escalation to ertapenem would
be useful for healthcare policymakers.
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